Literature DB >> 32370822

Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT.

Brian Davidson1, Kurinchi Gurusamy1, Neil Corrigan2, Julie Croft2, Sharon Ruddock2, Alison Pullan2, Julia Brown2, Maureen Twiddy3,4, Jaqueline Birtwistle3, Stephen Morris5, Nick Woodward6, Steve Bandula7, Daniel Hochhauser8, Raj Prasad9, Steven Olde Damink10, Marielle Coolson10, K van Laarhoven11, Johannes Hw de Wilt11.   

Abstract

BACKGROUND: Although surgical resection has been considered the only curative option for colorectal liver metastases, thermal ablation has recently been suggested as an alternative curative treatment. There have been no adequately powered trials comparing surgery with thermal ablation.
OBJECTIVES: Main objective - to compare the clinical effectiveness and cost-effectiveness of thermal ablation versus liver resection surgery in high surgical risk patients who would be eligible for liver resection. Pilot study objectives - to assess the feasibility of recruitment (through qualitative study), to assess the quality of ablations and liver resection surgery to determine acceptable standards for the main trial and to centrally review the reporting of computed tomography scan findings relating to ablation and outcomes and recurrence rate in both arms.
DESIGN: A prospective, international (UK and the Netherlands), multicentre, open, pragmatic, parallel-group, randomised controlled non-inferiority trial with a 1-year internal pilot study.
SETTING: Tertiary liver, pancreatic and gallbladder (hepatopancreatobiliary) centres in the UK and the Netherlands. PARTICIPANTS: Adults with a specialist multidisciplinary team diagnosis of colorectal liver metastases who are at high surgical risk because of their age, comorbidities or tumour burden and who would be suitable for liver resection or thermal ablation.
INTERVENTIONS: Thermal ablation conducted as per local policy (but centres were encouraged to recruit within Cardiovascular and Interventional Radiological Society of Europe guidelines) versus surgical liver resection performed as per centre protocol. MAIN OUTCOME MEASURES: Pilot study - patients' and clinicians' acceptability of the trial to assist in optimisation of recruitment. Primary outcome - disease-free survival at 2 years post randomisation. Secondary outcomes - overall survival, timing and site of recurrence, additional therapy after treatment failure, quality of life, complications, length of hospital stay, costs, trial acceptability, and disease-free survival measured from end of intervention. It was planned that 5-year survival data would be documented through record linkage. Randomisation was performed by minimisation incorporating a random element, and this was a non-blinded study.
RESULTS: In the pilot study over 1 year, a total of 366 patients with colorectal liver metastases were screened and 59 were considered eligible. Only nine participants were randomised. The trial was stopped early and none of the planned statistical analyses was performed. The key issues inhibiting recruitment included fewer than anticipated patients eligible for both treatments, misconceptions about the eligibility criteria for the trial, surgeons' preference for one of the treatments ('lack of clinical equipoise' among some of the surgeons in the centre) with unconscious bias towards surgery, patients' preference for one of the treatments, and lack of dedicated research nurses for the trial.
CONCLUSIONS: Recruitment feasibility was not demonstrated during the pilot stage of the trial; therefore, the trial closed early. In future, comparisons involving two very different treatments may benefit from an initial feasibility study or a longer period of internal pilot study to resolve these difficulties. Sufficient time should be allowed to set up arrangements through National Institute for Health Research (NIHR) Research Networks. TRIAL REGISTRATION: Current Controlled Trials ISRCTN52040363. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 21. See the NIHR Journals Library website for further project information.

Entities:  

Keywords:  ABLATION TECHNIQUES; COLORECTAL NEOPLASMS; COST–BENEFIT ANALYSIS; HEPATECTOMY; LIVER; NEOPLASM METASTASIS; RANDOMISED CONTROLLED TRIAL

Year:  2020        PMID: 32370822      PMCID: PMC7232132          DOI: 10.3310/hta24210

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  26 in total

1.  Qualitative research to improve RCT recruitment: issues arising in establishing research collaborations.

Authors:  Isabel de Salis; Zelda Tomlin; Merran Toerien; Jenny Donovan
Journal:  Contemp Clin Trials       Date:  2008-03-18       Impact factor: 2.226

2.  CIRSE Position Statement: Interventional Radiologists and Intra-arterial Stroke Therapy.

Authors:  Hans van Overhagen; Wim H van Zwam; Antonin Krajina; Jens Fiehler; Jim A Reekers; Saruhan Cekirge; John Thornton; Christoph A Binkert; Elias Brountzos; Afshin Gangi; Robert Morgan
Journal:  Cardiovasc Intervent Radiol       Date:  2018-10       Impact factor: 2.740

3.  Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.

Authors:  E Tanis; B Nordlinger; M Mauer; H Sorbye; F van Coevorden; T Gruenberger; P M Schlag; C J A Punt; J Ledermann; T J M Ruers
Journal:  Eur J Cancer       Date:  2014-01-07       Impact factor: 9.162

4.  Comparison between percutaneous radiofrequency ablation and surgical hepatectomy focusing on local disease control rate for colorectal liver metastases.

Authors:  Satoshi Nishiwada; Saiho Ko; Tomohide Mukogawa; Hirofumi Ishikawa; Masanori Matsusaka; Toshiya Nakatani; Eiryo Kikuchi; Akihiko Watanabe
Journal:  Hepatogastroenterology       Date:  2014 Mar-Apr

5.  Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma.

Authors:  T Shibata; T Niinobu; N Ogata; M Takami
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

6.  Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).

Authors:  Jenny L Donovan; Tim J Peters; Sian Noble; Philip Powell; David Gillatt; Steven E Oliver; J Athene Lane; David E Neal; Freddie C Hamdy
Journal:  J Clin Epidemiol       Date:  2003-07       Impact factor: 6.437

7.  It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials.

Authors:  Julia Wade; Jenny L Donovan; J Athene Lane; David E Neal; Freddie C Hamdy
Journal:  Soc Sci Med       Date:  2009-04-11       Impact factor: 4.634

8.  Recruiting patients into randomized clinical trials in surgery.

Authors:  J M Blazeby
Journal:  Br J Surg       Date:  2012-01-11       Impact factor: 6.939

9.  Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences.

Authors:  Nicola Mills; Jane M Blazeby; Freddie C Hamdy; David E Neal; Bruce Campbell; Caroline Wilson; Sangeetha Paramasivan; Jenny L Donovan
Journal:  Trials       Date:  2014-08-13       Impact factor: 2.279

10.  A new simple six-step model to promote recruitment to RCTs was developed and successfully implemented.

Authors:  Alba Realpe; Ann Adams; Peter Wall; Damian Griffin; Jenny L Donovan
Journal:  J Clin Epidemiol       Date:  2016-02-17       Impact factor: 6.437

View more
  5 in total

Review 1.  Interventional Treatment of Hepatic Metastases from Colorectal Cancer.

Authors:  Patrick D Sutphin; Suvranu Ganguli
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

2.  The current application of thermal ablation in colorectal liver metastasis.

Authors:  Zhongyi Zhang; Kun Yan
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

Review 3.  Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997-2020).

Authors:  Richard M Jacques; Rashida Ahmed; James Harper; Adya Ranjan; Isra Saeed; Rebecca M Simpson; Stephen J Walters
Journal:  BMJ Open       Date:  2022-02-14       Impact factor: 2.692

Review 4.  Solitary colorectal liver metastasis: overview of treatment strategies and role of prognostic factors.

Authors:  S Acciuffi; F Meyer; A Bauschke; R Croner; U Settmacher; A Altendorf-Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2021-12-16       Impact factor: 4.553

5.  Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-Year Analysis from the Prospective Amsterdam CORE Registry (AmCORE).

Authors:  Robbert S Puijk; Madelon Dijkstra; Bente A T van den Bemd; Alette H Ruarus; Sanne Nieuwenhuizen; Bart Geboers; Florentine E F Timmer; Evelien A C Schouten; Jan J J de Vries; Bram B van der Meijs; Karin Nielsen; Rutger-Jan Swijnenburg; M Petrousjka van den Tol; Kathelijn S Versteeg; Birgit I Lissenberg-Witte; Hester J Scheffer; Martijn R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2022-05-18       Impact factor: 2.797

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.